Education
About Us
Working with TipRanks
Follow Us
Ryvu Therapeutics SA (PL:RVU)
:RVU
Top Page
Ryvu Therapeutics SA
(Frankfurt:RVU)
Select Model
Select Model
Rating:38Underperform
Price Target:
zł25.00
▼(-11.82% Downside)
The overall stock score is primarily impacted by weak financial performance and technical analysis. The company's negative profitability and cash flow issues, combined with bearish technical indicators, contribute to a low score. The lack of positive valuation metrics further exacerbates the stock's unattractiveness.
Ryvu Therapeutics SA (RVU) vs. SPDR S&P 500 ETF (SPY)
Market Cap
€649.68M
Dividend YieldN/A
Average Volume (3M)26.90K
Price to Earnings (P/E)―
Beta (1Y)0.72
Revenue Growth15.45%
EPS Growth-25.81%
CountryPL
Employees328
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding23,120,148
10 Day Avg. Volume26,256
30 Day Avg. Volume26,899
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€24.98Price Target Upside-11.87% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering0
Ryvu Therapeutics SA Business Overview & Revenue Model
Company DescriptionRyvu Therapeutics SA (RVU) is a clinical-stage biopharmaceutical company based in Poland, focused on developing innovative therapies for the treatment of cancer. The company is primarily engaged in the discovery and development of small molecule drugs that target specific cancer pathways. Ryvu’s core products include its proprietary drug candidates, which are designed to improve outcomes for patients with various types of cancer, particularly through the modulation of the immune system and cell cycle processes.
How the Company Makes MoneyRyvu Therapeutics generates revenue primarily through the development and commercialization of its drug candidates. The company earns money through various streams including milestone payments from partnerships with larger pharmaceutical companies, licensing agreements, and potential royalties from product sales once drugs are commercialized. Additionally, Ryvu may receive funding through grants or subsidies aimed at supporting innovative research in oncology. Strategic collaborations with other biotech and pharmaceutical firms can also enhance its financial position, providing both upfront payments and shared development costs.
Ryvu Therapeutics SA Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
40
Negative
Cash Flow
35
Negative
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 77.97M | 46.86M | 38.80M | 11.19M | 15.41M |
| Gross Profit | 58.39M | 29.31M | 21.40M | -2.54M | 6.65M |
| EBITDA | -96.83M | -81.04M | -65.21M | -65.96M | -17.87M |
| Net Income | -111.44M | -92.11M | -83.78M | -79.08M | -31.69M |
Balance Sheet | |||||
| Total Assets | 378.78M | 403.20M | 474.98M | 228.81M | 295.64M |
| Cash, Cash Equivalents and Short-Term Investments | 225.40M | 233.67M | 102.44M | 88.23M | 161.19M |
| Total Debt | 75.51M | 906.00K | 2.77M | 5.07M | 7.41M |
| Total Liabilities | 234.89M | 143.61M | 131.59M | 59.39M | 71.92M |
| Stockholders Equity | 143.88M | 259.59M | 343.39M | 161.30M | 223.72M |
Cash Flow | |||||
| Free Cash Flow | -135.38M | -88.11M | 12.03M | -69.85M | -44.82M |
| Operating Cash Flow | -129.48M | -84.55M | 21.32M | -57.87M | -10.64M |
| Investing Cash Flow | 137.16M | -195.54M | 690.00K | 8.06M | -55.94M |
| Financing Cash Flow | 94.21M | 240.83M | -2.46M | -3.17M | 130.69M |
Ryvu Therapeutics SA Technical Analysis
Negative
28.35
Price Trends
28.99
Negative
29.99
Negative
29.17
Negative
Market Momentum
-0.27
Negative
52.10
Neutral
85.29
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PL:RVU, the sentiment is Negative. The current price of 28.35 is above the 20-day moving average (MA) of 27.89, below the 50-day MA of 28.99, and below the 200-day MA of 29.17, indicating a neutral trend. The MACD of -0.27 indicates Negative momentum. The RSI at 52.10 is Neutral, neither overbought nor oversold. The STOCH value of 85.29 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PL:RVU.
Ryvu Therapeutics SA Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | zł679.15M | 1,434.11 | ― | ― | 14.10% | -99.00% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | €143.04M | ― | -57.55% | ― | -74.16% | -192.42% | |
44 Neutral | €215.07M | ― | -83.02% | ― | -40.45% | 27.53% | |
38 Underperform | €649.68M | ― | -80.59% | ― | 15.45% | -25.81% |
* Healthcare Sector Average
PL:RVU
Ryvu Therapeutics SA
28.35
-24.35
-46.20%
PL:SVE
Biomed-Lublin Wytwornia Surowic i Szczepionek S.A.
4.23
-0.08
-1.86%
PL:CTX
Captor Therapeutics SA
38.00
-35.00
-47.95%
PL:MOC
OncoArendi Therapeutics SA
7.84
-3.76
-32.41%
PL:SLV
Selvita SA
37.00
-21.00
-36.21%
PL:MAB
Mabion SA
8.85
-7.33
-45.30%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.